2026 Revenue Forecasts: Novo vs. Lilly by the Numbers

Novo and Lilly are forecasting strong 2026 GLP-1 revenue growth despite price compression. Here's the combined $60B+ franchise outlook, broken down by product.

The 2026 GLP-1 revenue forecasts for Novo Nordisk and Eli Lilly capture a market at an inflection point: price compression is meaningful, but volume growth remains strong; new indications continue to expand demand; Medicare exposure is approaching; and pipeline products are emerging. Analyst consensus estimates and company guidance diverge on specific numbers but converge on the directional story.

This forecast review synthesizes publicly available 2025 company disclosures, Q4 2025 earnings guidance, sell-side analyst consensus, and disclosed pipeline milestones into a coherent picture of what 2026 and 2027 are likely to look like financially for the two dominant GLP-1 manufacturers.

Novo Nordisk 2026 Outlook

Novo Nordisk's 2025 annual report and Q4 2025 guidance outlined expectations for 2026. The company expects continued volume growth in the GLP-1 franchise driven by Wegovy (weight management, cardiovascular indication), Ozempic (diabetes), and emerging access through BALANCE and other Medicare channels. This volume growth is expected to partially but not entirely offset the pricing compression from the $349 NovoCare cash-pay program, authorized telehealth subscription pricing, and preparatory positioning for the January 2027 Medicare negotiated price effective date.

Net revenue growth for 2026 is guided at mid-to-high single digits on a constant-currency basis, with the GLP-1 franchise being the largest contributor. Operating margin is expected to compress modestly as pricing cuts flow through faster than volume growth. CagriSema commercial launch, pending regulatory approval, is a 2026-2027 upside variable not fully included in base guidance.

Eli Lilly 2026 Outlook

Eli Lilly's 2025 10-K and Q4 2025 earnings call outlined similar themes with different specifics. Tirzepatide franchise (Mounjaro for diabetes, Zepbound for weight management) is expected to continue strong volume growth driven by Zepbound expanded indications (OSA, cardiovascular where applicable), manufacturing capacity expansion enabling broader access, and continued commercial launch across international markets. Pricing compression from LillyDirect Zepbound vial pricing is a factor but is partially offset by dose-strength differentiation (starting dose $299, maintenance doses $449).

Lilly's guidance reflects expectations for continued double-digit revenue growth in 2026, with the tirzepatide franchise being the largest single contributor. Pipeline milestones — orforglipron ACHIEVE readouts, retatrutide TRIUMPH program progress, and continued label expansions for tirzepatide — represent additional upside beyond base guidance.

Comparative 2026 Revenue Expectations

These are approximate consensus ranges and will vary by specific analyst. Actual 2026 reported results will depend on price realization, volume growth, currency translation effects, and one-time items. The directional story — continued franchise growth with Zepbound gaining share and combined revenue approaching $60+ billion — is robust across methodologies.

Why Revenue Is Growing While Prices Are Falling

The apparent paradox — manufacturer revenue is growing despite substantial per-unit price cuts — is explained by volume. At $1,400 per month with limited access, Wegovy generated meaningful per-unit revenue from a relatively narrow patient base. At $349 per month with dramatically expanded access, it generates less per-unit revenue but serves a much larger population. The total revenue (price × volume) grows when volume growth outpaces price compression. The math is consistent with typical branded pharmaceutical market expansion patterns.

The 2027 Inflection

2026 guidance is relatively clean because the major pricing shock — the Medicare 71% semaglutide discount — doesn't take effect until January 1, 2027. 2027 and beyond introduces Medicare as a meaningful price-setter for semaglutide, with Lilly's tirzepatide following in later negotiation cycles. The 2027 outlook is accordingly more uncertain, with both upside (BALANCE-driven volume expansion, continued cash-pay penetration) and downside (Medicare price compression flowing through to commercial contracts) scenarios plausible.

Pipeline Contributions

Both companies' pipelines contribute meaningfully to the 2027+ outlook. Novo Nordisk's CagriSema (combination therapy) could launch in 2026-2027. Eli Lilly's orforglipron (oral) and retatrutide (triple agonist) could launch in 2027-2028. Each pipeline product represents potential franchise extension that offsets mature-product pricing pressure. The companies' long-term strategies assume the pipeline delivers, and investor sentiment is partially tied to continued pipeline progress.

What Could Change the Forecast

Several developments could materially alter the 2026-2027 revenue trajectory. Faster-than-expected generic entry (unlikely given patent timelines). Significant payer backlash against expanded coverage (possible but partially offset by evidence). Broader international price harmonization pressure (slowly building). Major pipeline disappointments (low probability based on current data). Each of these remains a watch item rather than a base-case concern.

For related reporting, see our SEC filings review, Medicare 71% analysis, and retatrutide phase 2 review.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.